Enliven Therapeutics CFO Benjamin Hohl Sells 3,350 Shares

On December 27th, Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), executed the sale of 3,350 shares of the company's stock. The shares were sold at an average price of $22.15 per share, culminating in a total transaction value of $74,202.50. This sale was formally reported in a filing with the Securities and Exchange Commission, which can be accessed through this link.

Further Trading Activities by Benjamin Hohl:

• On December 30th, Hohl sold an additional 900 shares at an average price of $22.51, resulting in a transaction worth $20,259.00.
• Earlier, on November 27th, he sold 5,250 shares at an average price of $24.89, totaling $130,672.50.
• On October 28th, he sold 6,250 shares for an average price of $28.56, collecting $178,500.00.
• On October 18th, Hohl sold 814 shares at an average price of $30.00, amounting to $24,420.00.
• On October 4th, he sold 10,218 shares at an average price of $27.51, resulting in $281,097.18.
• Lastly, on October 7th, Hohl sold 1,270 shares for an average price of $27.51, totaling $34,937.70.

Recent Stock Performance

On the trading day following Hohl's sale, shares of Enliven Therapeutics saw a modest increase of 0.5%, rising by $0.11 to reach $22.50. During midday trading, the stock's volume was 90,373 shares, contrasting with its average trading volume of 252,244 shares. The stock has a 50-day simple moving average of $25.45 and a 200-day simple moving average of $24.29. Enliven Therapeutics has a market capitalization of $1.10 billion, a price-to-earnings ratio of -11.84, and a beta of 1.02. The stock's performance over the past year has seen a low of $10.90 and a high of $30.03.

Analyst Ratings and Market Outlook

Various research analysts have recently shared insights on the performance of Enliven Therapeutics' shares. Notably, Robert W. Baird raised its price target for the stock from $32.00 to $40.00, assigning it an "outperform" rating in a report dated November 15th. Similarly, BTIG Research began coverage of the stock on December 13th with a "buy" rating and a price target of $42.00. Furthermore, HC Wainwright maintained a "buy" rating and set a $37.00 price target in a report from October 1st. The current ratings indicate that four investment analysts rate the stock as a buy while one suggests a strong buy. Based on MarketBeat's analysis, Enliven Therapeutics holds a consensus rating of "Buy" alongside an average price target of $38.25.

Company Overview:

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing small molecule inhibitors to assist cancer patients. The company's primary product candidates include ELVN-001, currently undergoing evaluation in a Phase 1 clinical trial for adults with chronic myeloid leukemia, and ELVN-002, in a Phase 1 clinical trial for adults with solid tumors containing HER2 alterations.

Institutional Stake Changes

Recent reports indicate that several hedge funds have made adjustments to their positions in Enliven Therapeutics. For instance, Quest Partners LLC increased its ownership in the firm by 87.3% during the second quarter, now holding 1,592 shares valued at $37,000 after acquiring an additional 742 shares. Additionally, China Universal Asset Management Co. Ltd. boosted its holdings by 64.4% in the third quarter, owning 9,085 shares worth $232,000 after procuring another 3,559 shares. Throughout the third quarter, SG Americas Securities LLC and Verition Fund Management LLC purchased new stakes valued at approximately $256,000 and $271,000, respectively. Overall, institutional investors now possess 95.08% of the company's shares.

Enliven, Shares, Stocks